We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Simple Blood Tests for Signaling Proteins Could Predict Cancer or Inflammation

By LabMedica International staff writers
Posted on 24 Feb 2023

Telomeres, sections of DNA found at the ends of our chromosomes, were first identified by scientists around 80 years ago. More...

Telomeres contain a unique DNA sequence consisting of endless repeats of TTAGGG bases that prevent chromosomes from sticking to each other. Telomeres were once believed to be incapable of encoding proteins due to their simple monotonous repetitions of DNA. Two decades ago, researchers demonstrated that the end of a telomere’s DNA loops back on itself to form a tiny circle, thereby hiding the end and blocking chromosome-to-chromosome fusions. When cells divide, telomeres shorten, eventually becoming so short that the cell is unable to divide properly anymore, leading to cell death. Now, the same researchers have found that telomeres hold a potent biological function that could be relevant to our understanding of cancer and aging.

Researchers at UNC School of Medicine (Chapel Hill, NC, USA) have made the stunning discovery that telomeres hold genetic information to produce two small proteins, one of which was found to be elevated in specific human cancer cells and cells from patients with telomere-related defects. In 2011, a group of researchers studying an inherited form of ALS found that an RNA molecule containing a six-base repeat could by a novel mechanism generate a series of toxic proteins consisting of two amino acids repeating one after the other. In the latest study, the researchers found a striking similarity of this RNA to the RNA generated from human telomeres, and believe that the same novel mechanism could be in play.

They conducted experiments to show how telomeric DNA can instruct the cell to produce signaling proteins termed as VR (valine-arginine) and GL (glycine-leucine). Signaling proteins are basically chemicals that trigger a chain reaction of other proteins inside cells that eventually lead to a biological function important for health or disease. The researchers then chemically synthesized VR and GL to examine their properties using powerful electron and confocal microscopes, accompanied by state-of-the-art biological methods. They found elevated amounts of VR protein in some human cancer cells and in cells from patients suffering from diseases as a result of defective telomeres.

“Based on our research, we think simple blood tests for these proteins could provide a valuable screen for certain cancers and other human diseases,” said Jack Griffith, the Kenan Distinguished Professor of Microbiology and Immunology and member of the UNC Lineberger Comprehensive Cancer Center. “These tests also could provide a measure of ‘telomere health,’ because we know telomeres shorten with age.”

“Many questions remain to be answered, but our biggest priority now is developing a simple blood test for these proteins. This could inform us of our biological age and also provide warnings of issues, such as cancer or inflammation,” added Griffith.

Related Links:
UNC School of Medicine 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Urinalysis Solution
UN-9000
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.